The prognostic impact of MGMT expression on low-grade gangliogliomas: A clinicopathological and immunohistochemical study

I. Wei Chang, Chao Tien Hsu, Jui Wei Lin, Chih Hsin Hung

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Ganglioglioma (GG) is an uncommon brain parenchymal neoplasm. Although most cases have indolent clinical behaviour, a subgroup of GGs does recur, especially in patients with unresectable disease. O6-methylguanine DNA methyltransferase (MGMT) is a DNA repair protein that removes mutagenic and cytotoxic adducts from O6-guanine in DNA. Lack of MGMT protein expression immunohistochemically is related to drug responses in patients with malignant glioma treated with alkylating agents. Furthermore, MGMT promoter methylation has also been investigated as an independent favourable prognostic factor for glioblastoma. The primary management is surgical resection for GGs and gross total resection is recommended. Despite infrequent use of chemotherapy for low-grade GGs, it was still introduced to a subset of patients, especially those who had unresectable disease. We assessed clinicopathological features of nine cases of low-grade GG to further elucidate the relationship between the status of the MGMT protein expression and the prognosis. This series included four men and five women with a mean age of 21.6 years at the first surgery. The mean postoperative follow-up period was 6 years. Only two patients had recurrent disease after 1.7 and 3.2 years of the first surgery. Immunohistochemically, 11.1% exhibited 3+ nuclear staining for MGMT protein, 11.1% exhibited 2+ staining, 33.3% exhibited 1+ staining, and 44.4% exhibited 0 staining. Tumours with more intensive MGMT protein expression (2+∼3+ immunostaining) tended to recur more frequently (p < 0.05), corresponding to the worse prognostic predictive value of intensive MGMT staining.

Original languageEnglish
Pages (from-to)275-282
Number of pages8
JournalFolia Neuropathologica
Volume51
Issue number4
DOIs
Publication statusPublished - Jan 1 2013
Externally publishedYes

Fingerprint

Ganglioglioma
Methyltransferases
Protein Methyltransferases
DNA
Staining and Labeling
Alkylating Agents
Guanine
Glioblastoma
Brain Neoplasms
Glioma
DNA Repair
Methylation
Drug Therapy

Keywords

  • Ganglioglioma
  • Low-grade
  • MGMT
  • WHO grade I

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology

Cite this

The prognostic impact of MGMT expression on low-grade gangliogliomas : A clinicopathological and immunohistochemical study. / Chang, I. Wei; Hsu, Chao Tien; Lin, Jui Wei; Hung, Chih Hsin.

In: Folia Neuropathologica, Vol. 51, No. 4, 01.01.2013, p. 275-282.

Research output: Contribution to journalArticle

@article{fa31d9ec2198405aa2585cc923be0b9b,
title = "The prognostic impact of MGMT expression on low-grade gangliogliomas: A clinicopathological and immunohistochemical study",
abstract = "Ganglioglioma (GG) is an uncommon brain parenchymal neoplasm. Although most cases have indolent clinical behaviour, a subgroup of GGs does recur, especially in patients with unresectable disease. O6-methylguanine DNA methyltransferase (MGMT) is a DNA repair protein that removes mutagenic and cytotoxic adducts from O6-guanine in DNA. Lack of MGMT protein expression immunohistochemically is related to drug responses in patients with malignant glioma treated with alkylating agents. Furthermore, MGMT promoter methylation has also been investigated as an independent favourable prognostic factor for glioblastoma. The primary management is surgical resection for GGs and gross total resection is recommended. Despite infrequent use of chemotherapy for low-grade GGs, it was still introduced to a subset of patients, especially those who had unresectable disease. We assessed clinicopathological features of nine cases of low-grade GG to further elucidate the relationship between the status of the MGMT protein expression and the prognosis. This series included four men and five women with a mean age of 21.6 years at the first surgery. The mean postoperative follow-up period was 6 years. Only two patients had recurrent disease after 1.7 and 3.2 years of the first surgery. Immunohistochemically, 11.1{\%} exhibited 3+ nuclear staining for MGMT protein, 11.1{\%} exhibited 2+ staining, 33.3{\%} exhibited 1+ staining, and 44.4{\%} exhibited 0 staining. Tumours with more intensive MGMT protein expression (2+∼3+ immunostaining) tended to recur more frequently (p < 0.05), corresponding to the worse prognostic predictive value of intensive MGMT staining.",
keywords = "Ganglioglioma, Low-grade, MGMT, WHO grade I",
author = "Chang, {I. Wei} and Hsu, {Chao Tien} and Lin, {Jui Wei} and Hung, {Chih Hsin}",
year = "2013",
month = "1",
day = "1",
doi = "10.5114/fn.2013.39716",
language = "English",
volume = "51",
pages = "275--282",
journal = "Folia Neuropathologica",
issn = "1641-4640",
publisher = "Termedia Publishing House Ltd.",
number = "4",

}

TY - JOUR

T1 - The prognostic impact of MGMT expression on low-grade gangliogliomas

T2 - A clinicopathological and immunohistochemical study

AU - Chang, I. Wei

AU - Hsu, Chao Tien

AU - Lin, Jui Wei

AU - Hung, Chih Hsin

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Ganglioglioma (GG) is an uncommon brain parenchymal neoplasm. Although most cases have indolent clinical behaviour, a subgroup of GGs does recur, especially in patients with unresectable disease. O6-methylguanine DNA methyltransferase (MGMT) is a DNA repair protein that removes mutagenic and cytotoxic adducts from O6-guanine in DNA. Lack of MGMT protein expression immunohistochemically is related to drug responses in patients with malignant glioma treated with alkylating agents. Furthermore, MGMT promoter methylation has also been investigated as an independent favourable prognostic factor for glioblastoma. The primary management is surgical resection for GGs and gross total resection is recommended. Despite infrequent use of chemotherapy for low-grade GGs, it was still introduced to a subset of patients, especially those who had unresectable disease. We assessed clinicopathological features of nine cases of low-grade GG to further elucidate the relationship between the status of the MGMT protein expression and the prognosis. This series included four men and five women with a mean age of 21.6 years at the first surgery. The mean postoperative follow-up period was 6 years. Only two patients had recurrent disease after 1.7 and 3.2 years of the first surgery. Immunohistochemically, 11.1% exhibited 3+ nuclear staining for MGMT protein, 11.1% exhibited 2+ staining, 33.3% exhibited 1+ staining, and 44.4% exhibited 0 staining. Tumours with more intensive MGMT protein expression (2+∼3+ immunostaining) tended to recur more frequently (p < 0.05), corresponding to the worse prognostic predictive value of intensive MGMT staining.

AB - Ganglioglioma (GG) is an uncommon brain parenchymal neoplasm. Although most cases have indolent clinical behaviour, a subgroup of GGs does recur, especially in patients with unresectable disease. O6-methylguanine DNA methyltransferase (MGMT) is a DNA repair protein that removes mutagenic and cytotoxic adducts from O6-guanine in DNA. Lack of MGMT protein expression immunohistochemically is related to drug responses in patients with malignant glioma treated with alkylating agents. Furthermore, MGMT promoter methylation has also been investigated as an independent favourable prognostic factor for glioblastoma. The primary management is surgical resection for GGs and gross total resection is recommended. Despite infrequent use of chemotherapy for low-grade GGs, it was still introduced to a subset of patients, especially those who had unresectable disease. We assessed clinicopathological features of nine cases of low-grade GG to further elucidate the relationship between the status of the MGMT protein expression and the prognosis. This series included four men and five women with a mean age of 21.6 years at the first surgery. The mean postoperative follow-up period was 6 years. Only two patients had recurrent disease after 1.7 and 3.2 years of the first surgery. Immunohistochemically, 11.1% exhibited 3+ nuclear staining for MGMT protein, 11.1% exhibited 2+ staining, 33.3% exhibited 1+ staining, and 44.4% exhibited 0 staining. Tumours with more intensive MGMT protein expression (2+∼3+ immunostaining) tended to recur more frequently (p < 0.05), corresponding to the worse prognostic predictive value of intensive MGMT staining.

KW - Ganglioglioma

KW - Low-grade

KW - MGMT

KW - WHO grade I

UR - http://www.scopus.com/inward/record.url?scp=84891794111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891794111&partnerID=8YFLogxK

U2 - 10.5114/fn.2013.39716

DO - 10.5114/fn.2013.39716

M3 - Article

C2 - 24374955

AN - SCOPUS:84891794111

VL - 51

SP - 275

EP - 282

JO - Folia Neuropathologica

JF - Folia Neuropathologica

SN - 1641-4640

IS - 4

ER -